MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Exagen Revenue 2011-2026 | XGN
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Exagen
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 52.5 M | 45.6 M | 48.3 M | 42 M | 40.4 M | 32.4 M | 26.8 M | - | 17.9 M | 11.7 M | 3.06 M | 926 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 52.5 M | 926 K | 29.2 M |
Quarterly Revenue Exagen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.2 M | 17.2 M | 15.5 M | - | 12.5 M | 15.1 M | 14.4 M | - | 13.4 M | 14.1 M | 11.2 M | - | 14.7 M | 7.61 M | 10.4 M | - | 12.3 M | 12.8 M | 10.6 M | - | - | 8.95 M | 9.58 M | - | 10.4 M | 10.5 M | 9.26 M | - | 8.22 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 17.2 M | 7.61 M | 12.2 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
41 M | $ 24.58 | 1.91 % | $ 99.4 M |  Israel |
 |
BioNano Genomics
BNGO
|
30.8 M | $ 1.12 | -0.88 % | $ 1.42 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
508 M | $ 28.4 | -1.41 % | $ 306 M |  China |
 |
Aspira Women's Health
AWH
|
8.18 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
DarioHealth Corp.
DRIO
|
20.4 M | $ 11.26 | - | $ 319 M | Israel |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
6.81 M | - | - | $ 79.8 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Fulgent Genetics
FLGT
|
283 M | $ 23.02 | 0.04 % | $ 696 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
Quest Diagnostics Incorporated
DGX
|
9.87 B | $ 209.34 | 0.95 % | $ 23.2 B | USA |
 |
Castle Biosciences
CSTL
|
332 M | $ 30.02 | 3.73 % | $ 834 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
280 M | $ 19.18 | 2.08 % | $ 1.03 B | USA |
 |
Danaher Corporation
DHR
|
24.6 B | $ 209.79 | -0.58 % | $ 153 B | USA |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
DexCom
DXCM
|
4.66 B | $ 72.99 | -0.38 % | $ 28.5 B | USA |
 |
Interpace Biosciences
IDXG
|
46.9 M | $ 1.74 | -5.95 % | $ 7.63 M | USA |
 |
Exact Sciences Corporation
EXAS
|
3.25 B | $ 103.46 | 0.07 % | $ 19.5 B | USA |
 |
Guardant Health
GH
|
982 M | $ 96.45 | 2.15 % | $ 12.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B |  Niderland |
 |
Laboratory Corporation of America Holdings
LH
|
14 B | $ 287.1 | 0.62 % | $ 24.1 B | USA |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 166.77 | 1.98 % | $ 8.27 B | USA |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
5.48 B | $ 104.81 | 0.14 % | $ 8.65 B |  Irlanda |
 |
ENDRA Life Sciences
NDRA
|
6.17 K | $ 3.77 | 0.53 % | $ 2.02 M | USA |
 |
IDEXX Laboratories
IDXX
|
4.3 B | $ 648.66 | 4.1 % | $ 52.2 B | USA |
 |
Illumina
ILMN
|
4.37 B | $ 123.46 | 2.42 % | $ 19.6 B | USA |
 |
IQVIA Holdings
IQV
|
16.3 B | $ 164.94 | 1.75 % | $ 28.4 B | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K | Israel |
 |
Koninklijke Philips N.V.
PHG
|
18 B | $ 31.48 | 0.82 % | $ 20 B | Niderland |
 |
Mettler-Toledo International
MTD
|
4.03 B | $ 1 382.99 | -0.81 % | $ 28.5 B |  Schweiz |
|
Biodesix
BDSX
|
71.3 M | $ 13.28 | 3.99 % | $ 1.72 B | USA |
 |
Quidel Corporation
QDEL
|
1.66 B | $ 22.06 | 4.11 % | $ 929 M | USA |
 |
Natera
NTRA
|
820 M | $ 209.72 | 0.18 % | $ 20.6 B | USA |
 |
Lantheus Holdings
LNTH
|
1.53 B | $ 73.43 | 0.01 % | $ 5.08 B | USA |
 |
Biomerica
BMRA
|
5.31 M | $ 2.11 | 0.49 % | $ 4.85 M | USA |
 |
Bioventus
BVS
|
512 M | $ 8.71 | 0.58 % | $ 546 M | USA |
 |
Medpace Holdings
MEDP
|
2.53 B | $ 442.92 | -0.46 % | $ 12.8 B | USA |